FindTrial
Sign In

Ertugliflozin 10 mg

DRUG5 trials

Sponsors

Merck Sharp & Dohme LLC, Shanghai Zhongshan Hospital

Conditions

Type 2 Diabetes MellitusType 2 Diabetes Mellitus Myocardial Infarction

Phase 3

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
CompletedNCT01958671
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2013-10-09End: 2016-07-28Updated: 2017-09-29
A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
CompletedNCT01986855
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2013-12-02End: 2016-09-28Updated: 2018-09-10
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
CompletedNCT01999218
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2013-12-16End: 2017-04-18Updated: 2019-04-02
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
CompletedNCT02099110
Merck Sharp & Dohme LLCType 2 Diabetes Mellitus
Start: 2014-04-22End: 2016-05-26Updated: 2018-09-12

Phase 4

Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial Infarction
Not yet recruitingNCT07621380
Shanghai Zhongshan HospitalType 2 Diabetes Mellitus Myocardial Infarction
Start: 2026-07-01End: 2028-03-01Target: 476Updated: 2026-06-24

Related Papers

Ertugliflozin + metformin as a treatment option for type 2 diabetes
Expert Opinion on Pharmacotherapy2021-06-164 citations
The effects of ertugliflozin on β‐cell function: Pooled analysis from four phase 3 randomized controlled studies
Diabetes Obesity and Metabolism2020-07-236 citations
Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials
Diabetes Therapy2020-07-0914 citations
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.
2020-05-0518 citations
Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus
Current Medical Research and Opinion2020-04-2310 citations
Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus
Current Medical Research and Opinion2020-04-233 citations
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials
Diabetologia2020-03-3140 citations
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
2020-01-039 citations
Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies
Diabetes and Vascular Disease Research2019-05-1325 citations
Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
Cardiovascular Diabetology2019-05-0720 citations
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin
Current Medical Research and Opinion2019-02-1450 citations
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
2018-02-2363 citations
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
2018-01-25118 citations
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
Diabetes Therapy2017-12-27106 citations
Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study.
2017-11-20111 citations